{"id":"W4411351237","doi":"10.1002/hon.70093_76","title":"76 | GLOFITAMAB PLUS GEMCITABINE AND OXALIPLATIN (Glofit‐GemOx) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): 2‐YEAR FOLLOW‐UP OF STARGLO","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Genentech; University College London; F. Hoffmann-La Roche; BeiGene; Sanofi","keywords":"Gemcitabine; Oxaliplatin; Diffuse large B-cell lymphoma; Refractory (planetary science); Medicine; Oncology; Lymphoma; Internal medicine; Chemotherapy; Materials science; Cancer; Colorectal cancer; Metallurgy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005118382,0.0003821521,0.001545809,0.000374822,0.00008552554,0.00001378807,0.000275325,0.0007014105,0.0002023108],"category_scores_gemma":[0.0008051427,0.0002736321,0.000125041,0.0007153784,0.0005344165,0.0001007272,0.0004615889,0.0004659593,0.00003285979],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006208538,"about_ca_system_score_gemma":0.004188496,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002082964,"about_ca_topic_score_gemma":0.0002296006,"domain_scores_codex":[0.9965458,0.0002919489,0.0009057024,0.0007558201,0.0005966036,0.000904139],"domain_scores_gemma":[0.9974896,0.001061379,0.0002613663,0.0006287448,0.0002613072,0.0002976589],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.04694111,0.04054671,0.8661659,0.003078549,0.0005773848,0.003343691,0.001557538,0.00001037899,0.0006608822,0.01750932,0.01113839,0.008470192],"study_design_scores_gemma":[0.7281867,0.008970447,0.2392252,0.0006559488,0.0002939725,0.0002012681,0.0009551958,0.001918611,0.00105367,0.0008622998,0.01705473,0.0006220094],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9892422,0.0008054829,0.0001108842,0.0004997047,0.0001885664,0.001166007,0.00003393918,0.00007510963,0.007878126],"genre_scores_gemma":[0.9965006,0.0001535233,0.001266001,0.0005443318,0.00002559065,0.00008326578,0.00008337524,0.00003424184,0.00130904],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6812455,"threshold_uncertainty_score":0.9999716,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01284584267870639,"score_gpt":0.2859185327758965,"score_spread":0.2730726900971901,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}